3Gress TW,Nieto FJ,Shahar E,et al.Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus:Atherosclerosis Risk in Communities Study[J].N Engl J Med,2000,342(13):905-912.
4Golden SH,Wang NY,Klag MJ, et al .Blood Pressure in Young Adulthood and the Risk of Type 2 Diabetes in Middle Age [ J ]. Diabetes Care. 2003.26(4) : 1110-1115.
5Sowers JR, Reed J. Clinical advisory treatment of hypertension in diabetes[J] .J Clin Hypertens,2000,2(2): 132-133.
6Lindholm LH. The outcome of STOP-Hypertension-2 in relation to the 1999 WHO/ISH hypertension guidelines [ J]. Blood Press, 2000, 9[ Suppl2]: 21-24.
7Hansson L,Lindholm LH,Niskanen L,et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project(CAPPP)randomised trial[J].Lancet,1999,353(9153):611-616.
8The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an anglotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients[J] .N Engl J Med,2000,342(3) : 145-153.
9UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39[J] .BMJ, 1998,317(7160) :713-720.
10Sowers JR,Bakris GL. Antihypertensive therapy and the risk of type 2 diahetes mellitus [J]. N Engl J Med, 2000,342 (13) : 969-970.
3Fujita M, Asanuma H, Kim J, el al. Impaired glucose tolerance: apossible contributor to left ventricular hypertrophy and diastolic dysfunction[J]. Int J Cardio, 2007, 118 (1): 76-80.
4Brohall G, Oden A, Fagerberg B. Carotid artery, intima-madia thickness in patientswith type 2 diabetesmellitus and impaired glucose to lerance: a systematic review [J ]. Diabetic Med, 2006, 23 (6) : 609-616.
